Cluster Headache Syndrome – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

    1.1. Report Overview

2. Cluster Headache Syndrome - Overview

3. Executive Summary

4. Cluster Headache Syndrome: Pipeline Assessment

    4.1. By Stage of Development

    4.2. By Route of Administration

    4.3. By Drug Class

    4.4. By Molecule Type

    4.5. By Therapy Area / Indication

    4.6. By Drug Target

    4.7. By Sponsor

5. Cluster Headache Syndrome: Company & Drug Profiles

    5.1. Clinical Stage

        5.1.1. Civamide nasal solution 0.01%– Winston Pharmaceuticals, Inc.

            5.1.1.1. Company Overview

            5.1.1.2. Product Description

            5.1.1.3. R&D Status & Development Activities

            5.1.1.4. Mechanism of Action

            5.1.1.5. Molecule Type

            5.1.1.6. Stage of Development

            5.1.1.7. Indications

            5.1.1.8. Route of Administration

            5.1.1.9. Funding

        5.1.2. ATI Neurostimulation System– Autonomic Technologies, Inc.

            5.1.2.1. Company Overview

            5.1.2.2. Product Description

            5.1.2.3. R&D Status & Development Activities

            5.1.2.4. Mechanism of Action

            5.1.2.5. Molecule Type

            5.1.2.6. Stage of Development

            5.1.2.7. Indications

            5.1.2.8. Route of Administration

            5.1.2.9. Funding

        5.1.3. Botulinum toxin type A – Norwegian University of Science and Technology

            5.1.3.1. Company Overview

            5.1.3.2. Product Description

            5.1.3.3. R&D Status & Development Activities

            5.1.3.4. Mechanism of Action

            5.1.3.5. Molecule Type

            5.1.3.6. Stage of Development

            5.1.3.7. Indications

            5.1.3.8. Route of Administration

            5.1.3.9. Funding

        5.1.4. Others

    5.2. Preclinical

        5.2.1. Company Overview

        5.2.2. Product Description

        5.2.3. R&D Status & Development Activities

        5.2.4. Mechanism of Action

        5.2.5. Molecule Type

        5.2.6. Indications

        5.2.7. Route of Administration

        5.2.8. Funding

6. Cluster Headache Syndrome: An Overview on Dormant & Discontinued Pipeline Candidates

    6.1. Overview

    6.2. Product Description

    6.3. Reason for Discontinuation

7. Cluster Headache Syndrome: Additional Key Insights

    7.1. Epidemiology Overview: Cluster Headache Syndrome

    7.2. Current Market Scenario: Cluster Headache Syndrome Therapeutics

8. Cluster Headache Syndrome: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.